Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Hepatocellular Carcinoma | Research

Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma

Authors: Ya Ma, Yue Gong, QingTao Qiu, Changsheng Ma, Shuang Yu

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Objective

To investigate the value of differential diagnosis of hepatocellular carcinoma (HCC) and non-hepatocellular carcinoma (non-HCC) based on CT and MR multiphase radiomics combined with different machine learning models and compare the diagnostic efficacy between different radiomics models.

Background

Primary liver cancer is one of the most common clinical malignancies, hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer, accounting for approximately 90% of cases. A clear diagnosis of HCC is important for the individualized treatment of patients with HCC. However, more sophisticated diagnostic modalities need to be explored.

Methods

This retrospective study included 211 patients with liver lesions: 97 HCC and 124 non-hepatocellular carcinoma (non-HCC) who underwent CT and MRI. Imaging data were used to obtain imaging features of lesions and radiomics regions of interest (ROI). The extracted imaging features were combined to construct different radiomics models. The clinical data and imaging features were then combined with radiomics features to construct the combined models. Support Vector Machine (SVM), K-nearest Neighbor (KNN), RandomForest (RF), eXtreme Gradient Boosting (XGBoost), Light Gradient Boosting Machine (LightGBM), Multilayer Perceptron (MLP) six machine learning models were used for training. Five-fold cross-validation was used to train the models, and ROC curves were used to analyze the diagnostic efficacy of each model and calculate the accuracy rate. Model training and efficacy test were performed as before.

Results

Statistical analysis showed that some clinical data (gender and concomitant cirrhosis) and imaging features (presence of envelope, marked enhancement in the arterial phase, rapid contouring in the portal phase, uniform density/signal and concomitant steatosis) were statistical differences (P < 0.001). The results of machine learning models showed that KNN had the best diagnostic efficacy. The results of the combined model showed that SVM had the best diagnostic efficacy, indicating that the combined model (accuracy 0.824) had better diagnostic efficacy than the radiomics-only model.

Conclusions

Our results demonstrate that the radiomic features of CT and MRI combined with machine learning models enable differential diagnosis of HCC and non-HCC (malignant, benign). The diagnostic model with dual radiomic had better diagnostic efficacy. The combined model was superior to the radiomic model alone.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
go back to reference McGlynn KA, London WT. Epidemiology and natural history of hepatocellular car cinoma. Best Pract Res Clin Gastroenterol. 2005;19(1):3–23.CrossRefPubMed McGlynn KA, London WT. Epidemiology and natural history of hepatocellular car cinoma. Best Pract Res Clin Gastroenterol. 2005;19(1):3–23.CrossRefPubMed
5.
go back to reference Chen X, Yang Z, Deng J. Use of 64-Slice spiral CT examinations for Hepatocellular Carcinoma (DR LU). J BUON. 2019;24(4):1435–40.PubMed Chen X, Yang Z, Deng J. Use of 64-Slice spiral CT examinations for Hepatocellular Carcinoma (DR LU). J BUON. 2019;24(4):1435–40.PubMed
10.
go back to reference Parmar C, Leijenaar RT, Grossmann P, Velazquez ER, Bussink J, Rietveld D, Rietbergen MM, Haibe-Kains B, Lambin P, Aerts HJ. Radiomic feature clusters and prognostic signatures specific forlung and head & neck cancer. Sci Rep. 2015;5:srep11044.CrossRef Parmar C, Leijenaar RT, Grossmann P, Velazquez ER, Bussink J, Rietveld D, Rietbergen MM, Haibe-Kains B, Lambin P, Aerts HJ. Radiomic feature clusters and prognostic signatures specific forlung and head & neck cancer. Sci Rep. 2015;5:srep11044.CrossRef
12.
go back to reference Bruix J, Sherman M. American Association for the Study of Liver Diseases. Manage- ment of hepatocellular carcinoma: an up- date. Hepatology. 2011;53(3):1020–2.CrossRefPubMed Bruix J, Sherman M. American Association for the Study of Liver Diseases. Manage- ment of hepatocellular carcinoma: an up- date. Hepatology. 2011;53(3):1020–2.CrossRefPubMed
13.
go back to reference Bruix J, Sherman M, Practice G, Committee. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.CrossRefPubMed Bruix J, Sherman M, Practice G, Committee. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.CrossRefPubMed
14.
go back to reference Joo I, Lee JM, Lee DH, Ahn SJ, Lee ES, Han JK. Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: comparison with multiphasic multidetector computed tomography. JMagn Reson Imaging. 2017;5(3):731–40.CrossRef Joo I, Lee JM, Lee DH, Ahn SJ, Lee ES, Han JK. Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: comparison with multiphasic multidetector computed tomography. JMagn Reson Imaging. 2017;5(3):731–40.CrossRef
15.
go back to reference Yue CHEN, Jie-ru XU, Zhong-ze YANG,ZHOU, Wei YANG, Qin-ting. XIONG Wen-jing,RANG Wei-qing.Incidence tendency of hepatocellular carcinoma in China, 2005–2015[J].Practical Preventive Medicine,2021,28(10):1180–1183. Yue CHEN, Jie-ru XU, Zhong-ze YANG,ZHOU, Wei YANG, Qin-ting. XIONG Wen-jing,RANG Wei-qing.Incidence tendency of hepatocellular carcinoma in China, 2005–2015[J].Practical Preventive Medicine,2021,28(10):1180–1183.
16.
go back to reference Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic. Find Radiol. 2009;250(2):435–43.CrossRef Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic. Find Radiol. 2009;250(2):435–43.CrossRef
17.
go back to reference Okuda K, Musha H, Nakajima Y, et al. Clinicopathologic features of encapsulated hepatocellular carcinoma: a study of 26 cases. Cancer. 1977;40(3):1240–5.CrossRefPubMed Okuda K, Musha H, Nakajima Y, et al. Clinicopathologic features of encapsulated hepatocellular carcinoma: a study of 26 cases. Cancer. 1977;40(3):1240–5.CrossRefPubMed
18.
go back to reference Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503.CrossRefPubMed Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503.CrossRefPubMed
19.
go back to reference Ishizaki M, Ashida K, Higashi T, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch. 2001;438(6):574–80.CrossRefPubMed Ishizaki M, Ashida K, Higashi T, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch. 2001;438(6):574–80.CrossRefPubMed
20.
go back to reference Kim TK, Lee KH, Jang HJ, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology. 2011;259(3):730–8.CrossRefPubMed Kim TK, Lee KH, Jang HJ, et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology. 2011;259(3):730–8.CrossRefPubMed
21.
go back to reference Rimola J, Forner A, Tremosini S, et al. Non-invasive diagnosis of hepatocellular carcinoma 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol. 2012;56(6):1317–23.CrossRefPubMed Rimola J, Forner A, Tremosini S, et al. Non-invasive diagnosis of hepatocellular carcinoma 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol. 2012;56(6):1317–23.CrossRefPubMed
22.
go back to reference Jang HJ, Kim TK, Khalili K, et al. Characterization of 1- to 2-cm liver nodules detected on hcc surveillance ultrasound according to the criteria of the American Association for the study of Liver Disease:is quadriphasic CT necessary? AJR Am J Roentgenol. 2013;201(2):314–21.CrossRefPubMed Jang HJ, Kim TK, Khalili K, et al. Characterization of 1- to 2-cm liver nodules detected on hcc surveillance ultrasound according to the criteria of the American Association for the study of Liver Disease:is quadriphasic CT necessary? AJR Am J Roentgenol. 2013;201(2):314–21.CrossRefPubMed
23.
go back to reference Bruix J, Sherman M, American Association for the Study of Liver Diseases. Manage Hepatocellular Carcinoma: Update Hepatol. 2011;53(3):1020–2. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Manage Hepatocellular Carcinoma: Update Hepatol. 2011;53(3):1020–2.
24.
go back to reference Cruite I, Tang A, Sirlin CB. Imagingbased diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol. 2013;201(1):41–55.CrossRefPubMed Cruite I, Tang A, Sirlin CB. Imagingbased diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol. 2013;201(1):41–55.CrossRefPubMed
26.
go back to reference Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology. 2015;61(3):1056–65.CrossRefPubMed Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology. 2015;61(3):1056–65.CrossRefPubMed
27.
go back to reference Earls JP, Theise ND, Weinreb JC, et al. Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology. 1996;201(1):207–14.CrossRefPubMed Earls JP, Theise ND, Weinreb JC, et al. Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology. 1996;201(1):207–14.CrossRefPubMed
28.
go back to reference Kojiro M. Histopathology of liver cancers.Best. Pract Res Clin Gastroenterol. 2005;19(1):39–62.CrossRef Kojiro M. Histopathology of liver cancers.Best. Pract Res Clin Gastroenterol. 2005;19(1):39–62.CrossRef
29.
30.
go back to reference Hu MJ, Yu YX, Fan YF, Hu CH. CT-based radiomics model to distinguish necrotic hepatocellular carcinoma from pyogenic liver abscess. Clin Radiol. 2021;76(2):161e. 11-161.e17.CrossRef Hu MJ, Yu YX, Fan YF, Hu CH. CT-based radiomics model to distinguish necrotic hepatocellular carcinoma from pyogenic liver abscess. Clin Radiol. 2021;76(2):161e. 11-161.e17.CrossRef
31.
go back to reference Huang F, Liu X, Liu P et al. The Application Value of MRI T2∗WI Radiomics Nomogram in discriminating Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma. Comput Math Methods Med. 2022;2022:7099476. Published 2022 Sep 27. https://doi.org/10.1155/2022/7099476 Huang F, Liu X, Liu P et al. The Application Value of MRI T2∗WI Radiomics Nomogram in discriminating Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma. Comput Math Methods Med. 2022;2022:7099476. Published 2022 Sep 27. https://​doi.​org/​10.​1155/​2022/​7099476
Metadata
Title
Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma
Authors
Ya Ma
Yue Gong
QingTao Qiu
Changsheng Ma
Shuang Yu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12109-9

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine